Drug combination and repurposing for cancer therapy: the example of breast cancer.
Breast cancer
Cancer
Drug combination
Drug repurposing
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
29
10
2020
revised:
30
12
2020
accepted:
07
01
2021
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Cancer is a set of extremely complex diseases, which are increasingly prominent today, as it affects and kills millions of people worldwide, being the subject of intense study both in its pathophysiology and therapy. Especially in women, breast cancer is still a cancer with a high incidence and mortality. Even though mortality rates for this type of cancer have declined in recent years, it remains challenging at the treatment level, especially the metastatic type. Due to all the impact on health, cancer therapy is the subject of costly and intense research. To enrich this therapy, as well as decrease its underlying high associated costs, drug repurposing and drug combinations are strategies that have been increasingly studied and addressed. As the name implies, drug repurposing presupposes giving new purposes to agents which, in this case, are approved for the therapy of other diseases (for example, cardiovascular or metabolic diseases), but are not approved for cancer therapy. Therefore, a better knowledge of these therapeutic modalities for breast cancer therapy is crucial for improved therapy. In this particular review, we will discuss some relevant aspects of cancer and, particularly, breast cancer and its therapy. Also, drug combination and repurposing will be highlighted, together with relevant examples. Despite some limitations that need to be overcome, these methodologies are extremely important and advantageous in combating several current problems of cancer therapy, namely in terms of costs and resistance to current therapeutic modalities. These approaches will be explored with a special focus on breast cancer.
Identifiants
pubmed: 33490692
doi: 10.1016/j.heliyon.2021.e05948
pii: S2405-8440(21)00053-0
pmc: PMC7810770
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e05948Informations de copyright
© 2021 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biomolecules. 2018 Dec 14;8(4):
pubmed: 30558247
Sci Rep. 2019 Aug 5;9(1):11336
pubmed: 31383893
Breast Cancer Res Treat. 2015 Jun;151(2):281-94
pubmed: 25904215
Apoptosis. 2015 Oct;20(10):1373-87
pubmed: 26276035
Oncologist. 2011;16(5):682-93
pubmed: 21478276
Neoplasma. 2019 Nov;66(6):963-970
pubmed: 31607128
Nat Rev Cancer. 2019 Mar;19(3):123-124
pubmed: 30683893
Oncotarget. 2017 Jan 10;8(2):2874-2889
pubmed: 27926515
Oncol Rep. 2016 Jun;35(6):3135-42
pubmed: 27035124
Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
J Natl Cancer Inst. 2012 Oct 17;104(20):1576-90
pubmed: 23042933
Future Oncol. 2018 Jun;14(13):1317-1332
pubmed: 29363994
Breast Cancer (Auckl). 2014 Oct 08;8:125-33
pubmed: 25336961
Trends Cancer. 2017 Aug;3(8):543-546
pubmed: 28780930
Pharmazie. 2015 Feb;70(2):117-22
pubmed: 25997252
J Thorac Oncol. 2013 May;8(5):619-23
pubmed: 23546045
Cancer Res. 2017 Feb 1;77(3):790-801
pubmed: 27940576
Breast Cancer Res Treat. 2019 Nov;178(2):327-335
pubmed: 31392517
BMC Cancer. 2019 Oct 24;19(1):996
pubmed: 31651285
J Natl Compr Canc Netw. 2017 Mar;15(3):370-398
pubmed: 28275037
Cancer Treat Res. 2019;171:1-20
pubmed: 30552653
Breast Cancer Res Treat. 2013 Apr;138(2):499-508
pubmed: 23471651
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061
Colloids Surf B Biointerfaces. 2012 Jun 15;95:195-200
pubmed: 22445746
Nat Commun. 2016 Mar 01;7:10634
pubmed: 26925549
Drug Discov Today. 2016 Feb;21(2):225-38
pubmed: 26360051
Int J Gynaecol Obstet. 2015 Oct;131 Suppl 1:S36-9
pubmed: 26433503
Oncotarget. 2019 Mar 12;10(21):2055-2067
pubmed: 31007848
Ecancermedicalscience. 2014 Jul 10;8:442
pubmed: 25075216
Pharmacol Res. 2017 Oct;124:74-91
pubmed: 28712971
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
J Natl Cancer Inst. 2018 Nov 20;:
pubmed: 30462268
Nat Rev Clin Oncol. 2015 Dec;12(12):732-42
pubmed: 26483297
Breast Cancer Res Treat. 2012 Jul;134(2):881-8
pubmed: 22622810
Ecancermedicalscience. 2018 Jun 18;12:ed82
pubmed: 30034523
J Cell Biochem. 2017 Jun;118(6):1412-1422
pubmed: 27859674
J Pers Med. 2020 Oct 29;10(4):
pubmed: 33138097
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Anticancer Agents Med Chem. 2017;17(1):21-28
pubmed: 27039923
Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110
pubmed: 25510809
Ecancermedicalscience. 2017 Nov 23;11:781
pubmed: 29225688
Nature. 2016 Jun 14;534(7607):314-6
pubmed: 27306171
Nat Rev Drug Discov. 2009 Feb;8(2):111-28
pubmed: 19180105
NPJ Precis Oncol. 2019 Jan 28;3:3
pubmed: 30701196
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Curr Oncol Rep. 2017 Jul;19(7):48
pubmed: 28597105
Int J Oncol. 2019 Feb;54(2):407-419
pubmed: 30570109
Cancer. 1975 Jul;36(1):90-7
pubmed: 1203853
Comput Struct Biotechnol J. 2015 Sep 25;13:504-13
pubmed: 26949479
J Pathol. 2018 Jan;244(1):49-60
pubmed: 28940209
JAMA Oncol. 2019 Oct 01;5(10):1448-1455
pubmed: 31393548
Front Oncol. 2017 Nov 14;7:273
pubmed: 29184849
Front Med (Lausanne). 2017 Nov 29;4:211
pubmed: 29238707
Oncol Lett. 2017 Sep;14(3):2587-2597
pubmed: 28927025
J Transl Med. 2016 Sep 20;14:269
pubmed: 27646033
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Oncol Rep. 2010 Nov;24(5):1121-31
pubmed: 20878101
Aging (Albany NY). 2017 May 31;9(5):1357-1358
pubmed: 28562314
Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10284-9
pubmed: 19487683
Oncotarget. 2017 Dec 8;9(2):2158-2174
pubmed: 29416762
SLAS Discov. 2020 Sep;25(8):923-938
pubmed: 32441190
ESMO Open. 2018 Feb 2;3(2):e000285
pubmed: 29464109
Oncologist. 2002;7 Suppl 6:13-9
pubmed: 12454315
Nature. 2019 Apr;568(7751):254-258
pubmed: 30842661
Breast Cancer (Dove Med Press). 2017 Dec 01;9:559-565
pubmed: 29238220
Br J Anaesth. 2014 Jul;113 Suppl 1:i82-7
pubmed: 24464611
Cell Commun Signal. 2020 Mar 5;18(1):36
pubmed: 32138738
Biochem Pharmacol. 2019 Jun;164:326-335
pubmed: 31028743
Pharmacol Res Perspect. 2015 Jun;3(3):e00149
pubmed: 26171228
J Pain Palliat Care Pharmacother. 2008;22(1):45-46
pubmed: 28792816
Mol Endocrinol. 2004 Feb;18(2):402-11
pubmed: 14605097
Cell Stem Cell. 2014 Mar 6;14(3):275-91
pubmed: 24607403
Oncologist. 2019 Nov;24(11):1439-1445
pubmed: 31420468
Am J Cancer Res. 2015 Dec 15;6(1):97-104
pubmed: 27073727
Nat Biotechnol. 2017 May;35(5):463-474
pubmed: 28319085